Booming Pharma Sector in India

Booming Pharma Sector in India

India, a US$ 8.2 Billion pharmaceutical market, represents one of the most emerging pharmaceutical markets in the world. According to the RNCOS latest report “Booming Pharma Sector in India”, in near future, the potential and opportunities within this market will increase by several folds. The market, presently driven by over a billion population, an expanding GDP, and rapid epidemiological transitions, is expected to be the major player in the global pharmaceutical market both in terms of its large domestic market and also as a pharmaceutical export hub.

The research study contains unique market-based research and provides detailed and objective analysis on the Indian pharmaceutical market. It presents a thorough statistical and analytical overview on the Indian pharmaceutical market, and provides past, present and future data on the entire structure, composition and working of the Indian pharmaceutical market. The research extensively discusses the opportunities and challenges that are expected to arise within and from the pharmaceutical market.

Research Highlights

• Between 2007-08 and 2011-12, the Indian domestic pharmaceutical market is expected to grow at a CAGR of nearly 16%.c
  
  
• The size of the domestic pharmaceutical market is larger than export market. However, owing to the growth of global generics market, stringent price controls in the domestic market, and better margins, the export market is growing much faster than the domestic market.
  
  
• Traditional branded generics presently dominate the Indian pharmaceutical market but the future will see strong growth in the specialty branded generics and patented drug segments.
  
  
• Drugs for diabetes and cardiovascular diseases are expected to see the fastest growth among all therapy areas during 2007-2011.
  
  
• The retail pharmaceutical market in India is presently highly unorganized; however, a vast opportunity exists for the organized market.
  
  
• Over the last few years, Cipla, Ranbaxy and GlaxoSmithKline are controlling the top three positions in the Indian pharmaceutical market.

The Report Covers

• Analysis of past, current and future market trends.
  
  
• Market study by segment.
  
  
• Discussion about the major drivers of the pharmaceutical market.
  
  
• Analysis of opportunities created by the market.
  
  
• Evaluation of major challenges for the market.
  
  
• Review on the government regulations.
  
  
• Competitive landscape of the market.

Research Methodology Used

Information Sources
Information has been sourced from books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.

Analysis Methods
The analysis methods include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis. 
 

1. Analyst View

2. Global Pharmaceutical Market

3. India - The Emerging Market

4. India - Macroeconomic & Healthcare Profile

4.1 Macroeconomic Profile

4.2 Population Profile

4.3 Healthcare Profile

5. Indian Pharmaceutical Market

5.1 Turnover

5.2 Trade

5.2.1 Export

5.2.2 Import

5.3 Bulk Drugs & Formulations

6. Domestic Pharmaceutical Market

6.1 What Makes the Market so Lucrative?

6.1.1 Ageing Population

6.1.2 Increasing Income

6.1.3 Product Patent Regime

6.1.4 Medical Infrastructure

6.1.5 Prevalence of Lifestyle-related Diseases

6.2 Market Size

6.3 Market Segmentation

6.3.1 By Drugs

6.3.1.1 Traditional Branded Generics

6.3.1.2 Specialty Branded Generics

6.3.1.3 Generic Generics

6.3.1.4 Patented Drugs

6.3.2 By Therapeutics

6.3.2.1 Acute Segment

6.3.2.1.1 Anti-infectives

6.3.2.1.2 Gastrointestinal

6.3.2.1.3 Vitamins/Minerals/Nutrients

6.3.2.1.4 Pain/Analgesics

6.3.2.1.5 Dermatology

6.3.2.1.6 Gynecology

6.3.2.1.7 Respiratory

6.3.2.2 Chronic Segment

6.3.2.2.1 Cardiac

6.3.2.2.2 Neuro/CNS

6.3.2.2.3 Anti-diabetic

6.4 Market Structure

6.5 Key Players

6.6 Future Outlook

6.6.1 Market Drivers & Restraints

6.6.2 Sales (2008-09 to 2011-12)

7. Government Regulations & Market Entry

7.1 Industrial & Manufacturing License

7.2 Patent Laws

7.3 Research & Development

7.4 Pricing

7.5 Market Entry

8. Opportunities

8.1 Biogenerics

8.2 Rural Markets

8.3 Pharma Outsourcing Market

8.4 Bioinformatics

8.5 Health Insurance

8.6 Drug Delivery & Packaging Industry

8.7 Pharmaceutical Retail Chains

9. Roadblocks

9.1 Lack of Innovation

9.2 Drug Price Controls & Low Margins

9.3 Low Per Capita Spending on Drugs

9.4 Multinationals Reluctant to Invest in India

9.5 Counterfeit Drugs

9.6 Government Financing

10. Profile of Key Players

10.1 Ranbaxy Laboratories Limited

10.2 Cipla Limited

10.3 GlaxoSmithKline Pharmaceuticals Limited

10.4 Nicholas Piramal India Limited

10.5 Zydus Cadila

List of Figures:

Figure 2-1: Global - Pharmaceutical Market (in Billion US$), 2002, 2006, 2007 & 2012F

Figure 3-1: Global - Top Pharmaceutical Markets (in Billion US$), 2005

Figure 3-2: Global - Forecast for Top Pharmaceutical Markets (in Billion US$), 2015

Figure 3-3: Global - CAGR of Top Pharmaceutical Markets (%), 2005 to 2015

Figure 4-1: India - Nominal GDP (in Billion US$), 2001-2007

Figure 4-2: India - Forecast for Nominal GDP (in Billion US$) 2008*-2011

Figure 4-3: India - Consumer Price Index (%), 2001-2007

Figure 4-4: India - Forecast for Consumer Price Index (%), 2008*-2011

Figure 4-5: India - Total FDI (in Billion US$), 2002-03 to 2007-08

Figure 4-6: India - FDI in Pharmaceutical Sector (in Million US$), 2003-04 to 2006-07

Figure 4-7: India - Population (in Billion), 2003-2007

Figure 4-8: India - Forecast for Population (in Billion), 2008*-2011

Figure 4-9: India - Population by Gender (%), 2003-2006

Figure 4-10: India - Population Breakup by Age (%), 2003-2007

Figure 4-11: India - Forecast for Population Breakup by Age (%), 2008*-2011

Figure 4-12: India - Per Head Healthcare Spending (in US$), 2001-2007

Figure 4-13: India - Forecast for Per Head Healthcare Spending (in US$), 2008*-2011

Figure 4-14: India - Healthcare Payments by Source (%), 2006

Figure 4-15: India - Number of Doctors (in ‘000) 2005-2007E

Figure 4-16: India - Forecast for Number of Doctors (in ‘000), 2008-2011

Figure 4-17: India - Number of Nurses (in ‘000), 2004-2007E

Figure 4-18: India - Forecast for Number of Nurses (in ‘000), 2008-2011

Figure 4-19: India - Number of Hospital Beds (in ‘000), 2004-2007E

Figure 4-20: India - Forecast for Number of Hospital Beds (in ‘000), 2008-2011

Figure 4-21: India - Number of Deaths due to Leading Causes (in ‘000), 2005

Figure 4-22: India - Leading Causes of Death (%), 2005

Figure 4-23: India - Forecast for Leading Causes of Death (%), 2030

Figure 5-1: India - Pharmaceutical Market Turnover* (in Billion INR), 2001-02 to 2007-08

Figure 5-2: India - Breakup of Pharmaceutical Market (%), 2007-08

Figure 5-3: India - Pharmaceutical Exports (in Billion INR), 2000-01 to 2007-08

Figure 5-4: India - Major API Exports (in Billion INR), 2005-06

Figure 5-5: India - Major Dosage Form Exports (in Billion INR), 2005-06

Figure 5-6: India - Pharmaceutical Exports by Region (%), 2005-06

Figure 5-7: India - Forecast for Pharmaceutical Exports (in Billion INR), 2008-09 to 2011-12

Figure 5-8: India - Pharmaceutical Imports (in Billion INR), 2000-01 to 2007-08E

Figure 5-9: India - Pharmaceutical Imports by Group (%), 2005

Figure 5-10: India - Bulk Drugs Production* (in Billion INR), 2001-02 to 2007-08E

Figure 5-11: India - Formulations Production* (in Billion INR), 2001-02 to 2007-08E

Figure 6-1: India - Population of People above 65 Years (in Million), 2003-2007E

Figure 6-2: India - Income Distribution among Households (%), 1989-90, 2001-02 & 2006-07E

Figure 6-3: India - Prevalence of Lifestyle-related Diseases (%), 2005

Figure 6-4: India - Share of Mass & Specialty Therapies in Pharmaceutical Market (%), 2004, 2006 & 2015F

Figure 6-5: India - Domestic Pharmaceutical Market* (in Billion INR), 2001-02 to 2007-08

Figure 6-6: India - Domestic Pharmaceutical Market by Drug Category (%), 2004

Figure 6-7: India - Forecast for Domestic Pharmaceutical Market by Drug Category (%), 2010

Figure 6-8: India - Traditional Branded Generics Market (in Billion US$), 2004 & 2010F

Figure 6-9: India - Specialty Branded Generics Market (in Billion US$), 2004 & 2010F

Figure 6-10: India - Generic Generics Market (in Billion US$), 2004 & 2010F

Figure 6-11: India - Patented Drugs Market (in Billion US$), 2004 & 2010F

Figure 6-12: India - Domestic Pharmaceutical Market by Therapeutic Category (%), 2007

Figure 6-13: India - CAGR Growth of Major Therapeutic Categories (%), 2007 to 2011

Figure 6-14: India - Anti-infectives Market (in Billion INR), 2006, 2007 & 2011F

Figure 6-15: India - Gastrointestinal Drugs Market (in Billion INR), 2006, 2007 & 2011F

Figure 6-16: India - Vitamins/Minerals/Nutrients Market (in Billion INR), 2006, 2007 & 2011F

Figure 6-17: India - Pain/Analgesics Market (in Billion INR), 2006, 2007 & 2011F

Figure 6-18: India - Dermatology Market (in Billion INR), 2006, 2007 & 2011F

Figure 6-19: India - Gynecology Market (in Billion INR), 2006, 2007 & 2011F

Figure 6-20: India - Number of Asthma Patients (in Million), 2005 & 2015F

Figure 6-21: India - Respiratory Drugs Market (in Billion INR), 2006, 2007 & 2011F

Figure 6-22: India - Number of Coronary Heart Patients (in Million), 2005 & 2015F

Figure 6-23: India - Cardiac Drugs Market (in Billion INR), 2006, 2007 & 2011F

Figure 6-24: India - Neuro/CNS Drugs Market (in Billion INR), 2006, 2007 & 2011F

Figure 6-25: India - Number of Diabetes Patients (in Million), 2005 & 2015F

Figure 6-26: India - Diabetes Market (in Billion INR), 2006, 2007 & 2011F

Figure 6-27: India - Share of Companies in Pharmaceutical Market (%), 2006

Figure 6-28: India - Income Distribution among Households (%), 2006-07* & 2011-12F

Figure 6-29: India - Forecast for Prevalence of Lifestyle-related Diseases (%), 2015

Figure 6-30: India - Forecast for Population of People above 65 Years (in Million), 2008-2011

Figure 6-31: India - Forecast for Domestic Pharmaceutical Market* (in Billion INR), 2008-09 to 2011-12

Figure 8-1: Global - Biogenerics Market (in Million US$), 2006 & 2011F

Figure 8-2: India - Pharmaceutical Market by Geographical Tier (%), 2005

Figure 8-3: India - Forecast for Pharmaceutical Market by Geographical Tier (%), 2011

Figure 8-4: India - Pharma Outsourcing Market (in Million US$), 2004, 2006 & 2007E

Figure 8-5: India - Pharma Outsourcing Market by Segment (%), 2006

Figure 8-6: India - Forecast for Pharma Outsourcing Market (in Million US$), 2008-2011

Figure 8-7: India - Forecast for Pharma Outsourcing Market by Segment (%), 2011

Figure 8-8: India - Bioinformatics Market (in Million US$), 2002-03 to 2006-07 & 2011-12F

Figure 8-9: India - Health Insurance Market (in Billion INR), 2001-02, 2006-07 & 2011-12F

Figure 8-10: India - Drug Packaging Market (in Billion INR), 2006-07* & 2011-12F

Figure 9-1: India & Global - Proportion of Revenue Spent on R&D (%), 2005

Figure 9-2: India - Spending on R&D (in Million US$), 2000-01 to 2005-06

Figure 9-3: Global - Per Capita Drug Consumption in Top Pharmaceutical Markets (in US$), 2006

Figure 9-4: Global - Share of State & Personal Financing in Top Pharmaceutical Markets (%), 2006

List of Tables:

Table 2-1: Global - Market Share & Growth of Leading Therapy Classes (%), 2006

Table 2-2: Global - Pharmaceutical Market by Region (in Billion US$), 2007

Table 5-1: India - Pharmaceutical Exports to Top Countries (in Million US$), 2003-2005

Table 5-2: India - Pharmaceutical Imports from Top Countries (in Million US$), 2003-2005

Table 6-1: India - Top 20 Pharmaceutical Companies by Retail Sales (in Million INR), 2006

Table 6-2: India - Top 20 Pharmaceutical Companies by Retail Sales (in Million INR), 2007

Table 7-1: India - Launch of Patented Drugs by Product & Company

Table 8-1: India - Number of Drug Delivery Companies by Formulation Type (1999, 2003 & 2007E)

Table 8-2: India - Expansion Plans of Pharmacy Retail Chains

Table 9-1: India - Counterfeit Drugs in Domestic Pharmaceutical Market